Navigation Links
Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of,GVAX Immunotherapy for Pancreatic Cancer

esothelin (p=.01). The new findings were presented over the weekend by Daniel Laheru, M.D., assistant professor of medical oncology at Johns Hopkins Kimmel Cancer Center, and colleagues, at the 2007 American Society of Clinical Oncology (ASCO) annual meeting being held in Chicago, IL.

"We continue to be encouraged by the survival data analysis, as well as the immunologic data reported today in this Phase 2 study of GVAX immunotherapy for pancreatic cancer in patients with operable disease," said Kristen Hege, M.D., vice president of Clinical Research at Cell Genesys. "We look forward to the results of ongoing studies conducted by Johns Hopkins which include a study of booster administrations to patients in the completed Phase 2 trial as well as a second 60-patient Phase 2 trial of GVAX immunotherapy with booster administrations following pancreatic cancer surgery and adjuvant radiation and chemotherapy. In addition, we are also looking forward to the results of a third ongoing Phase 2 trial in patients with metastatic pancreatic cancer also being conducted by Johns Hopkins, which is evaluating GVAX immunotherapy in combination with Erbitux(R), an antibody to the EGF receptor."

The Phase 2 study reported today was designed to evaluate the safety and efficacy of GVAX immunotherapy for pancreatic cancer which is being developed as a non patient-specific "off-the-shelf" pharmaceutical product. All patients underwent extensive surgical resection of their tumors. The immunotherapy was administered as an intradermal (under the skin) injection before and after standard post-operative adjuvant radiation therapy and 5- flourouracil chemotherapy. Patients received up to five doses -- the first prior to adjuvant chemoradiotherapy, the next three following adjuvant therapy at approximately one-month intervals and the fifth as a booster injection six months later. Patients were monitored for evidence of relapse an
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces a Broad, Patient-Specific Antibody Response
2. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
(Date:7/11/2014)... CHAPEL HILL, N.C. , July 11, 2014 ... component of pharmaceutical marketing and, consequently, organizations are ... specifically for patients. As part of ... learned it,s important to educate, communicate and engage ... from disease awareness to patient empowerment. By mapping ...
(Date:7/11/2014)... DUBLIN , July 11, 2014 ... the "Global and Chinese Medical X-ray Film Industry ... http://photos.prnewswire.com/prnh/20130307/600769 Global And ... professional and in-depth study on the current state of ... on the Chinese situation. The report provides a ...
(Date:7/11/2014)... July 11, 2014  Kindred Hospital Houston Northwest, ... the opening of its new outpatient wound healing ... to people with chronic, hard to heal wounds. ... lead to amputation, lower leg wounds related to ... closure, and traumatic injury wounds which are complex ...
Breaking Medicine Technology:New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2Global and Chinese Medical X-ray Film Industry Report 2014 2Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2
... Feb. 17, 2011 Reportlinker.com announces that ... in its catalogue: Antivirals ... Combination Therapies to be Major Drivers HIV ... http://www.reportlinker.com/p0397049/Antivirals-Market-to-2016---Antiretroviral-Agents-and-Combination-Therapies-to-be-Major-Drivers-HIV-and-Hepatitis-C-Markets.html Antivirals Market ...
... Medical Devices, Inc. announced today that it has selected ... Schein Inc. (Nasdaq: HSIC ), the largest ... dental, medical and veterinary practitioners, as the exclusive distributor ... is the first and only surgical tourniquet single-use device ...
Cached Medicine Technology:Reportlinker Adds Antivirals Market to 2016 - Antiretroviral Agents and Combination Therapies to be Major Drivers HIV and Hepatitis C Markets 2Reportlinker Adds Antivirals Market to 2016 - Antiretroviral Agents and Combination Therapies to be Major Drivers HIV and Hepatitis C Markets 3OHK Medical Devices Selects Henry Schein as Exclusive Distributor of HemaClear® 2OHK Medical Devices Selects Henry Schein as Exclusive Distributor of HemaClear® 3
(Date:7/11/2014)... The report, “Specialty Synthetic Fibers & Glass Fiber ... defines and segments the specialty synthetic fibers and ... of the volumes and values of types such ... UHMW Polyethylene, carbon fiber, partially oxidized polyacrylonitrile fiber, ... fiber, and liquid crystal polymer fiber and glass ...
(Date:7/11/2014)... 11, 2014 Datalogic brings a new ... sanitation hospital wide. With their new Gryphon GD4400 ... disease, like the devastating MRSA, which claimed 5,500 lives, ... GD4400-HC 2D and the Gryphon GM4400-HC 2D readers ... can even read barcodes off of troublesome LCD monitors, ...
(Date:7/11/2014)... 2014 Operators and owners ... in fuel costs now that model 2019 ... GHG standards are phasing in 2014-2018 ... themselves to install new features into their ... technologies , 2.    Efficient driveline components which reduce ...
(Date:7/11/2014)... News) -- Children who have emergency surgery on ... potentially even death than those who have weekday ... the Johns Hopkins researchers noted that the risk ... data on nearly 440,000 simple emergency surgeries that ... 22-year period. The surgeries are considered generally ...
(Date:7/11/2014)... July 11, 2014 Ticket Down is ... Concord Pavilion . When it comes to the summer concert ... The 37-year-old Georgia native is one of the biggest names in ... business. Bryan is currently out on his “That’s My Kind of ... stops the tour will be making through the rest of the ...
Breaking Medicine News(10 mins):Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 2Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 4Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 2Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 3Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3Health News:Emergency Surgeries on Weekends Riskier for Kids: Study 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 3
... Majority of New Kidney Failure Cases Consistently Found in ... 11 Kidney Care Partners (KCP) -- ... and manufacturers working together to improve the quality of ... -- in partnership with the National Minority Quality Forum, ...
... Award-winning singer advocates for research into disease afflicting ... artist LeAnn Rimes shared her personal story on ... and she encouraged lawmakers to support much-needed research ... disease."I was first diagnosed with psoriasis at age ...
... MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ) today ... Company 29th Annual Health Care Conference on Tuesday, March 17, ... of the presentation will be available on the Investor Relations ... replay will also be available within 24 hours for seven ...
... , , WEDNESDAY, March 11 (HealthDay News) -- In yet another ... research shows that overweight children as young as age 3 ... , About 24 percent of U.S. children aged 2 to ... in the 85th percentile or above for their height and ...
... Incorporated (Nasdaq: VPHM ) today announced that ... will present at the Cowen & Company 29th Annual ... 18, 2009. The conference is being held at ... live for investors through www.viropharma.com and available ...
... Md., March 11 Carolyn M. Clancy, M.D., director of ... appointment of three new members of the U.S. Preventive Services ... Melnikow, M.D., M.P.H., of Sacramento; and Wanda Nicholson, M.D., M.P.H., ... , , The Task Force, which is ...
Cached Medicine News:Health News:Kidney Care Partners and National Minority Quality Forum Call for Prevention Programs in Disease 'Hot Spots' 2Health News:Kidney Care Partners and National Minority Quality Forum Call for Prevention Programs in Disease 'Hot Spots' 3Health News:LeAnn Rimes Shares Her Personal Struggle With Psoriasis in Nation's Capital 2Health News:LeAnn Rimes Shares Her Personal Struggle With Psoriasis in Nation's Capital 3Health News:LeAnn Rimes Shares Her Personal Struggle With Psoriasis in Nation's Capital 4Health News:Overweight Preschoolers Raise Their Heart Disease Risk 2Health News:Overweight Preschoolers Raise Their Heart Disease Risk 3Health News:ViroPharma to Present at the Cowen & Company 29th Annual Healthcare Conference 2Health News:AHRQ Announces New Members of the U.S. Preventive Services Task Force 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: